Head-to-head · WeighScore
CoreAge Rx vs Direct Meds
The verdict
CoreAge Rx takes it — 89.5/100 to 77.6/100.
CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
CoreAge Rx scores 89.5/100 (B+).
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | CoreAge Rx | Direct Meds |
|---|---|---|
| WeighScore | 89.5/100 | 77.6/100 |
| Grade | B+ | C+ |
| Site position | #1 | #35 |
| Semaglutide | $99/mo | $249/mo sublingual · $297/mo injectable |
| Tirzepatide | $149/mo | $299/mo sublingual · $399/mo injectable |
| Coverage | All 50 states | Not publicly listed |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Yes |
Site position #1 · B+
Strengths
- Advertises the same medication price at every dose
- Semaglutide and tirzepatide injection options
- No membership fee; standard prescription shipping included unless checkout states otherwise
Where it loses points
- Compounded only; no FDA-approved brand option listed
- Dispensing pharmacy not identified on the reviewed product pages
- Applicable $50–$100 consultation fee is nonrefundable after review begins
- Orders become final after approval and pharmacy transmission; 30-day refund cutoff also applies
Site position #35 · C+
FDAWarning letter issued to directmeds.com, Inc. dba DirectMeds in September 2025. See the FDA warning-letter database.
Strengths
- Rare oral/sublingual option in addition to injectable
- All-inclusive pricing with no separate membership fee
- Both molecules — semaglutide and tirzepatide
- Intro promotional pricing near $147
Where it loses points
- Compounded only — not FDA-approved
- Pricing is company-stated, not independently live-verified
- Newer and somewhat ambiguous (operates across multiple domains)
- States served are not disclosed
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.